You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1946 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Aug 2024
Regimen
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Liposomal Daunorubicin and Liposomal Cytarabine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Dec 2023
Regimen
Intent: Adjuvant
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides
Sep 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria
Jan 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Mar 2025
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Locally Advanced Basal Cell Carcinoma
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
May 2019

Pages